By Jutta Schulze

In a recent conversation with Small Cap Nation’s Joya Dass, LumiThera’s CEO Clark Tedford shared some insight of his visit to Europe, where the company is seeking to launch its product in the first quarter of this year with the help of colleagues and collaborators. Their medical device treats visual conditions through non-invasive, cost-effective light therapy.

Tedford explained that their mission right now is to get the product approved in Europe and Canada first, and convince opinion-leaders to help with marketing the product to medical staff within the next four months. In a next step, their medical device will be launched in the United States as well.

The LumiThera LT-300 is part of a new generation of medical devices that encourage the body to heal itself by stimulating the cells in the retina to prevent age-related macular degeneration that impairs the vision. As a result, the cells’ performance in terms of fighting the disease is improved. Additionally, the instrument is unique in that it can be used in any ophthalmologist’s office for treatments that take less than five minutes.

LumiThera has set out to offer a solution in areas of vision loss where there is:

• No treatment available nowadays
• A growth in the population expected within the next few years - such as diabetic macular edema.

According to Tedford, the LT-300 can achieve a variety of other applications, which makes it especially interesting as a stand-alone device, offering painless and economic treatments to patients all around the world.

Disclosures: The author, Jutta Schulze, holds no interest in any of the securities or entities mentioned above. He has not received compensation for this article, other than from Small Cap Nation. The statements above do not constitute recommendations. The article has been based on publicly available information, and seeks to be unbiased and non-promotional.